Serodus ASA has in letter dated 28 November 2016 pursuant to the Continuing Obligations section 15.1 (4), cf. the Stock Exchange Act section 25 (1), applied for delisting of the company's shares from Oslo Axess.
Novel article on SER100 in patients with isolated systolic hypertension is published in Journal of Clinical Pharmacology in Drug Development
Oslo, 19 December 2016: Serodus (Oslo Axess: SER), are pleased to inform that an article on SER100 has been published in the Journal of Clinical Pharmacology in Drug Development under the title “Safety, tolerability and antihypertensive effect of SER100, an Opiate Receptor-Like 1 (ORL-1) partial agonist, in Patients with Isolated Systolic Hypertension”. The article will soon be available.
Serodus ASA applied the 29th of November 2016 for a delisting from Oslo Axess. As the company has emphasized an open and transparent process we have developed a Q&A about the possible delisting based on actual queries from some of our stakeholders.
Oslo, 28. November, Serodus today announced that the Phase 2a study of SER150 in Diabetic Nephropathy completed enrollment with the last patient in cohort2 being dosed the last dose.
Oslo, Norway, 21 November 2016 – Serodus ASA (OSE: SER) held an extraordinary general meeting on 21 November 2016 at 15:00 PM CET.
Reference is made to the voluntary offer document dated 30. October 2016 (the “Voluntary offer”) made by Viggo Harboe Holding 2006 ApS to acquire all issued and outstanding share in Serodus ASA.
Oslo, (01.10.2016) Serodus will hold an Extraordinary General Meeting 21 November 2016 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 5.
Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016
Reference is made to the stock exchange notice by Serodus ASA on 11 October 2016 and the stock exchange notice published by Oslo Børs today regarding approval of the voluntary offer document. Viggo Harboe holding 2006 Aps has launched a voluntary offer to acquire all issued and outstanding shares in Serodus ASA at a price of NOK 1.30 per share. In connection with the Offer, Shareholders representing in aggregate approximately 53.51 % of the Company’s share capital have irrevocably undertaken not to accept the Offer and a subsequent mandatory offer (if applicable), in addition to the Offeror holds 20.2%.
Oslo, 27. October 2016. Serodus ASA (OAX:SER) announces its results for the third quarter 2016.
Oslo, 25. October 2016 Serodus (OSE: SER) today announced that the Office of Orphan Products Development, United States Food and Drug Administration (FDA) has granted an Orphan Drug Designation for SER100 in pulmonary arterial hypertension (PAH).
Serodus ASA is pleased to invite shareholders, investors and other stakeholders to a presentation on both Monday 24. October 2016 at 16:00-17:00, and Tuesday 25. October 2016 at 09:00-10:00. The two sessions will cover the same subjects.
Oslo, October 14, 2016: Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 84 583 shares at an average price of NOK 1,15 per share. After registration of these shares Dr. Steiness has 2 353 437 shares and 100 000 warrants. The shareholdings of Dr. Eva Steiness is after this be 5.29%.
Oslo, Norway, 11 October 2016 – Serodus ASA (OSE: SER): Reference is made to the stock exchange notice on September 30th, 2016. Management has tested the interest for delisting Serodus from the Oslo Stock Exchange by having discussions with central shareholders. As part of these discussions the main owner of Serodus has indicate a willingness to give a voluntary offer of NOK 1.30 per share provided that a significant part of the share capital is willing to maintain their ownerships and continue to support the company in the delisting process.
Oslo, Norway, 30 September 2016 – Serodus ASA (OSE: SER): Reference is made to the 2. Quarterly report 2016 where Serodus stated that an evaluation of the financing model including the listing at Oslo Axess will be made.
Oslo, Norway, 22 September 2016 – Serodus ASA (OSE: SER) held an extraordinary general meeting on 22 September 2016 at 15:00 PM CET.
Proposal from the nomination committee to the general assembly meeting of Serodus ASA 22. September 2016
Serodus ASA are currently developing a pipeline of compounds within diabetes and diabetic comorbidities. The lead candidate within Diabetic Nephropathy is approaching the finalization of the Phase 2a safety study. The Nomination Committee propose to strengthen the Board of Directors with additional international experience.
Oslo, (31 August 2016) reference is made to the stock exchange announcement by Serodus ASA (the "Company") dated 29 June 2016 regarding the completed private placement of shares in the Company, raising gross proceeds of approximately NOK 10 million (the "Private Placement").
Oslo, (31.08.2016) Serodus will hold an Extraordinary General Meeting 22 September 2016 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 4.
Oslo, 18. August 2016. Serodus ASA (OAX:SER) announces its results for the second quarter 2016.
Oslo, 16. August 2016 - Reference is made to the stock exchange notice published by Serodus ASA (the "Company") on 29 June 2016 regarding a successfully completed NOK 10 million private placement.
Oslo – 15. August 2016 – Serodus ASA (Oslo Axess, SER) will present the Q2 results 2016 t at Hotel Continental, Stortingsgaten 24/26, Oslo, Thursday 18 August 2016 at 08:30. The presentation will be held by CEO Eva Steiness, CFO Tore Kvam.
Reference is made to stock exchange announcement on 27 April 2016 regarding Annual Report 2015. The responsibility statement from the Board of Directors and the CEO was due to a technical error not included in the Annual Report 2015. The complete Annual Report for 2015 has been republished and is available on Serodus website, www.serodus.com.
Oslo, June 30, 2016: With reference to the previous announcement regarding the private placement:
Reference is made to Serodus ASA's (the "Company") previous announcements regarding the private placement.
Oslo, 29. June 2016 – Serodus ASA (OSE:SER) has completed a private placement of 7 692 307 new shares at a subscription price of NOK 1.30 per share, raising a gross proceed of NOK 10 million.
Oslo, 27. June 2016 Board member Christina Carnegie who has served as a member of the Board of Serodus since June 2015 has informed the Board of Directors about her wishes to step out of the Board of Directors due to personal reasons. The Board of Directors will together with the Nomination committee initiate the process for her replacement.
Serodus announces that the first patient is randomized into the second cohort of the SER150 Ph2a study in Diabetic Nephropathy
Oslo, 20. June 2016 Serodus (OSE: SER) today has randomized the first patient into the second and last cohort of the SER150 study in Diabetic Nephropathy. Patients are dosed with 30mg SER150 twice daily for one month followed by one month of follow up.
Oslo, 01. June 2016 - Serodus (OSE: SER) today received approval from the central German Ethics committee to initiate recruitment into the second cohort of the SER150 study in Diabetic Nephropathy.
Oslo, Norway, 24 May 2016 – Serodus ASA (OSE: SER) held its annual general meeting on 24 May 2016 at 15:00 PM CET.
Serodus (Oslo Axess: SER) today announced that the Data Safety Monitoring Board (DSMB) has issued a positive recommendation regarding the data from cohort 1 of the ongoing Ph2a study of SER150 in Diabetic Nephropathy. The Chairman of the DSMB, Professor Dr Christoph Wanner stated: ”The DSMB has no safety concerns”. The DSMB reviewing all data from the ongoing trial at 10 sites in Germany. Special emphasis was placed on the safety profile of the drug.
Serodus today announced that the National Kidney Foundation (US) has invited Serodus to join a collaboration between the Food and Drug Administration (FDA), the European Medical Agency (EMA) and the NKF on the value of albuminuria as a clinical trial endpoint over the next couple of years.
Serodus ASA, Oslo, Norway, 4th of May 2016 (Oslo Axess: SER), a biotechnology company focusing new therapeutic treatment within diabetes and cardiovascular diseases announces that Jürgen Langhärig, Vice President Business Development, will present Serodus at BioEquity Europe in Copenhagen, Denmark on Wednesday 11 May 2016.
Oslo, (03.05.2016) The annual general meeting of Serodus ASA will be held on 24 May 2016 at 15:00 at Forskningsparken, Gaustadalleen 21, 0349 Oslo. Meetingroom Hagen 1.
SER130 for reducing scar size in Acute Myocardial Infarction Patent, composition of matter, allowed in China
Oslo, April 29, 2015: Serodus ASA (Oslo Axess: SER), today announced that State Intellectual Property Office of the People's Republic of China (SIPO) has granted to Serodus patent entitled, “IL-4-derived peptides”. The patent covers methods for treating various diseases caused by inflammation. This patent is currently pending in a number of other jurisdictions.
The Board of Directors of Serodus ASA has today approved the Annual Report 2015 including complete 2015 Annual Accounts with notes. The report is available on Serodus website in the section /Investor/Reports/Annual-reports.
Oslo, 27. April 2016. Serodus ASA (OAX:SER) announces its results for the first quarter 2016.
Oslo – 25. April 2016 – Serodus ASA (Oslo Axess, SER) will present the company and future strategy to investors and shareholders at Hotel Radisson Blu Royal, Hammerichs gade 1, København, on Monday 2nd of May 2016 at 16:00. The presentation will be held by CEO Eva Steiness and the rest of the management group. Please notify participation by e-mail to email@example.com.
Oslo – 20. April 2016 – Serodus ASA (Oslo Axess, SER) will present the Q1 results 2016 together with an overview of the lead drug candidate SER150 Diabetic Nephropathy and business development in Serodus at Hotel Continental, Stortingsgaten 24/26, Oslo, Wednesday 27 April 2016 at 08:00. The presentation will be held by CEO Eva Steiness, CFO Tore Kvam, VP Drug Development Nikolai Brun and VP Business Development Jürgen Langhärig.
PCT SER100 patent application filed - Serodus demonstrates a novel mechanism of action in Pulmonary Hypertension
Oslo, April 18, 2016: Serodus ASA (Oslo Axess: SER) has filed a PCT patent application for the Orphan Disease of Pulmonary Hypertension to the United Kingdom patent office.
Oslo, April 13, 2016: Serodus ASA (Oslo Axess: SER) has today published a new company presentation on the company’s web page. The presentation is available under: http://www.serodus.com/Investor/Presentations-Publications/Factsheet-company-presentation
Oslo, 07. April 2016. Serodus ASA (OAX:SER) announce that VP Drug Development Nikolai C. Brun has been invited to present at EuroDIA; Title: “Industry Perspective on Today’s Challenges and Opportunities in the Clinical Development of Biopharmaceuticals” in Hamburg, Germany, April 8th, 2016 at 4PM.
Oslo, 04. April 2016. Serodus ASA (OAX:SER) today announce that the company has initiated work to evaluate the company’s financing alternatives as part of planning a further development of the lead projects to next development stages - which also goes beyond the end of 2016.
Oslo, 30. March 2016. Serodus ASA (OAX:SER) Serodus ASA has entered into a market making agreement with Norne Securities AS with effect from 30 March 2016. The purpose of the agreement is to increase liquidity in trading of the company’s shares and the agreement is in accordance with the standard requirements set by Oslo Stock Exchange.”
Oslo, 17. February 2016. Serodus ASA (OAX:SER) announces its results for the fourth quarter 2015.
Oslo, 15. February 2016: Serodus ASA is pleased to announce that the European Patent Office (EPO) has approved the patent application No. PCT/DK2012/000022 (12710122.8) covering the peptide SER140.
Oslo – 12. February 2016 – Serodus ASA (Oslo Axess, SER) will present the Q4 results 2015 at Hotel Continental, Stortingsgaten 24/26, Oslo, Wednesday 17 February 2016 at 08:00. The presentation will be held by CEO Eva Steiness and CFO Tore Kvam.
Oslo, February 5, 2016: Serodus (Oslo Axess: SER), are pleased to inform that an article on SER140 has been published in the Journal of Diabetes Research under the title ” The IL-1β Receptor Antagonist SER140 Postpones the Onset of Diabetes in Female Nonobese Diabetic Mice”. The article is available on http://www.hindawi.com/journals/jdr/2016/7484601/.
Serodus announces completion of patient enrollment of the first cohort in Phase 2a clinical trial of SER150 in patients with Diabetic Nephropathy
Oslo, February 3, 2016: Serodus (Oslo Axess: SER), today announced that the last patient in the first cohort was randomized into the SER150 multi-center, double-blind, randomized, placebo controlled Phase 2a clinical trial in patients suffering from Diabetic nephropathy. SER150 is a first-in-class anti-inflammatory compound, with a dual thromboxane (anti thrombotic) mode of action.
Oslo, Norway, 19. January 2016: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces, that Anthony Rosenberg has joined the company as an advisor. SERODUS is in the process of building a strong group of advisors to assist management in business development, strategy, licensing and corporate development.
San Francisco, USA, 15. January 2016: Serodus ASA (Oslo Axess: SER) participated in the JP Morgan conference and presented the company and its drug candidates to numerous investors and pharmaceutical companies present in San Francisco.
Oslo, Norway, 12 January 2016: Serodus ASA (SER) (Oslo Axess) today announced that the manuscript “The IL-1b receptor antagonist SER140 postpones the onset of diabetes in female non-obese diabetic mice” has been accepted for publication in in the Journal of Diabetic Research and will shortly be available electronically. Serodus’ compound, SER140 significantly delays the development of diabetes in the NOD mice, a well-recognized experimental diabetes model.
Oslo, Norway, 11 January 2016: Serodus ASA (Oslo Axess: SER), a company focusing on the development of novel treatment of cardiovascular and metabolic diseases, announces the formation of a new Scientific Advisory Board for the development program in Type 2 Diabetes (SER140).